



Stimunity received the BIOVISION 2016 Catalyzer Special Award

Paris, April 14, 2016 -- Stimunity is pleased to announce that today the company has received the BIOVISION 2016 Catalyzer Special Award. This award was created to give some visibility to high potential startups and accelerate the fundraising process by putting them directly in contact with potential investors.

Stimunity was part of the 18 projects selected from hundreds of applicants by the committee co-chaired by Marc Bonneville, Vice-President of Medical and Scientific Department at Institut Mérieux and Alexander von Gabain, co-founder & ex-CSO of Intercell AG (merged with Valneva, developing vaccines), to pitch for a 10min presentation followed by the traditional questions & answers. The competition was tough but the jury was convinced by the potential of the STING pathway in immunotherapy, and the relevance of addressing this target with a biologic Virus-Like particle.

“It’s a pleasure to receive this prize” said Sylvain Carlioz co-founder and CEO of Stimunity. “It is also a recognition of all the work we have done before starting the company, and it’s always nice to see that other people shared our innovative approach.”

About Biovision

Biovision was founded in Lyon in 1999 on the initiative of Raymond Barre, former Prime Minister, Vice-President of the European Commission and Mayor of Lyon, as well as Francois Gros, Permanent Secretary of the French Academy of Sciences. They considered the life sciences as the pathway to excellence for the capital and for the Rhône-Alpes region. Bolstered by the support of international organizations as well as the European Commission, research centers, laboratories, leading NGOs in the field and many other partners in the public and private spheres, Biovision has established itself as a meeting place for international stakeholders in the health sector as well as an internationally recognized model for its dedication to innovation. Biovision is organized by Fondation pour l’Université de Lyon. More information at www.biovision.org

About Stimunity

Stimunity is a startup company from Institut Curie and develops biopharmaceuticals to treat patients that still do not respond to conventional immunotherapy in infectious disease and cancer. Stimunity focuses on the STING pathway, which is known to activate the innate immune system, and induce a T-CD8 response against pathogens and tumor cells. By addressing this target with a unique approach which combines the the endogenous STING activator encapsulated in a Virus-Like Particle (VLP), Stimunity’s drugs are best-in-class. More information at www.stimunity.com or contact@stimunity.com.